Medicare Enrolled
Dr. Lihong Wu, M.D.
Hematology & Oncology · Long Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wu from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wu?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wu
Dr. Lihong Wu is a hematology & oncology specialist in Long Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Wu performed 112,204 Medicare services across 1,915 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wu received a total of $5,074 from 44 pharmaceutical and/or device companies across 254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wu is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 6% volume in CA
$5,074 industry payments
Medicare Practice Summary
Medicare Utilization ↗112,204
Medicare services
Top 6% in CA for hematology & oncology
1,915
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,905 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
32,250 | $1 | $4 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
21,420 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 16,600 | $43 | $193 |
| Romosozumab injection (Evenity) for osteoporosis | 11,550 | $8 | $36 |
| Denosumab injection (Prolia/Xgeva) | 9,660 | $18 | $83 |
| Anti-nausea injection (aprepitant) | 5,720 | $1 | $6 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
3,480 | $36 | $159 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,396 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 1,816 | $0 | $0 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,650 | $6 | $28 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
879 | $65 | $237 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
756 | $14 | $93 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
597 | $12 | $81 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
507 | $104 | $481 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
395 | $120 | $606 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
390 | $58 | $269 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
239 | $1 | $4 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
216 | $18 | $88 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
183 | $146 | $672 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
151 | $1 | $24 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
121 | $11 | $69 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
114 | $1 | $6 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
108 | $100 | $400 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
90 | $26 | $147 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
90 | $25 | $134 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
83 | $59 | $295 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
78 | $6 | $29 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
74 | $106 | $459 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
67 | $145 | $520 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
60 | $30 | $134 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
55 | $25 | $109 |
| New patient office visit, complex (60-74 min) | 53 | $165 | $821 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
50 | $29 | $220 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
44 | $32 | $200 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
44 | $83 | $479 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 39 | $14 | $62 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
38 | $2 | $9 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
36 | $4 | $20 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
28 | $70 | $306 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
27 | $72 | $341 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
27 | $38 | $176 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
23 | $77 | $394 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.0% high complexity
64.9% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,074
Total received (2018-2024)
Avg $725/year across 7 years
Top 43% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
254
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,845 (95.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$229 (4.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$37
2023
$21
2022
$182
2021
$315
2020
$746
2019
$1,832
2018
$1,941
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$37
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$451
Novartis Pharmaceuticals Corporation
$351
Merck Sharp & Dohme Corporation
$349
AstraZeneca Pharmaceuticals LP
$348
E.R. Squibb & Sons, L.L.C.
$338
Amgen Inc.
$309
PFIZER INC.
$293
Astellas Pharma US Inc
$266
Bayer HealthCare Pharmaceuticals Inc.
$251
Janssen Biotech, Inc.
$249
Lilly USA, LLC
$203
Exelixis Inc.
$146
Celgene Corporation
$141
Clovis Oncology, Inc.
$125
Pharmacyclics LLC, An AbbVie Company
$112
Takeda Pharmaceuticals U.S.A., Inc.
$98
Regeneron Healthcare Solutions, Inc.
$92
Incyte Corporation
$88
Gilead Sciences, Inc.
$85
GENZYME CORPORATION
$75
Boehringer Ingelheim Pharmaceuticals, Inc.
$59
TESARO, Inc.
$56
TerSera Therapeutics LLC
$52
Seagen Inc.
$48
Foundation Medicine, Inc.
$46
AMAG Pharmaceuticals, Inc.
$44
Daiichi Sankyo Inc.
$40
EMD Serono, Inc.
$40
Alexion Pharmaceuticals, Inc.
$28
Ipsen Biopharmaceuticals, Inc
$27
Seattle Genetics, Inc.
$26
Emmaus Medical, Inc.
$23
GlaxoSmithKline, LLC.
$22
Mirati Therapeutics, Inc.
$21
Janssen Pharmaceuticals, Inc
$21
Karyopharm Therapeutics Inc.
$19
Helsinn Therapeutics (U.S.), Inc.
$19
AbbVie, Inc.
$19
Teva Pharmaceuticals USA, Inc.
$18
Partner Therapeutics, Inc.
$18
Eisai Inc.
$17
INSYS Therapeutics Inc
$16
Innate Pharma, Inc
$13
ARRAY BIOPHARMA INC
$12
Top 3 companies account for 22.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BOSULIF · BRAFTOVI · Bavencio · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ERBITUX · EVENITY · Endari · Enhertu · Erleada · FERAHEME · FOUNDATIONONE · GAZYVA · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LEUKINE · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · Lumoxiti · MONJUVI · MVASI · Neulasta · Nexavar · Nplate · OPDIVO · PADCEV · PROMACTA · Perjeta · REBLOZYL · RETACRIT · RYDAPT · Revlimid · Rubraca · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Stivarga · TAGRISSO · TECENTRIQ · TUKYSA · ULTOMIRIS · VENCLEXTA · VOTRIENT · Venclexta · Vitrakvi · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · ZEJULA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
397
Per 100K population
4.0
County median income
$87,760
Nearest hospital
ST MARY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Wu is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Wu experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Wu performed 32,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wu receive payments from pharmaceutical companies?
Yes. Dr. Wu received a total of $5,074 from 44 companies across 254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wu's costs compare to other hematology & oncology specialists in Long Beach?
Dr. Wu's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wu) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Long Beach
Browse hematology & oncology specialists in Long Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology